Department of Health
and Human Services (HHS)
and Human Services (HHS)
January 6, 2022
PAR-21-183 - Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
NOT-DA-21-042 - Notice of Change to Key Dates for NIDA PAR-21-183, " Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)"
National Institute on Drug Abuse (NIDA)
This Notice informs applicants of changes to the Key Dates for Funding Opportunity Announcement (FOA) PAR-21-183, "Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)".
The following Section of PAR-21-183 has been modified to reflect the changed dates.The dates have also changed in NOT-DA-21-042:
Currently Reads:
Part 1. Overview Information
Key Dates
Open Date (Earliest Submission Date):
August 8, 2021
Letter of Intent Due Date(s):
30 days prior to application due date
|
Application Due Dates |
Review and Award Cycles |
||||
|
New |
Renewal / Resubmission / Revision (as allowed) |
AIDS |
Scientific Merit Review |
Advisory Council Review |
Earliest Start Date |
|
August 4, 2021 |
August 4, 2021 |
August 4, 2021, |
November 2021 |
January 2022 |
April 2022 |
|
December 6, 2021 |
December 6, 2021 |
December 6, 2021 |
March 2022 |
May 2022 |
July 2022 |
|
August 4, 2022 |
August 4,, 2022 |
August 4, , 2022 |
November 2022 |
January 2023 |
April 2023 |
|
December 6, 2022 |
December 6, 2022 |
December 6, 2022 |
March 2023 |
May 2023 |
July 2023 |
|
August 4, 2023 |
August 4, 2023 |
August 4, 2023 |
November 2023 |
January 2024 |
April 2024 |
|
December 6, 2023 |
December 6, 2023 |
December 6, 2023 |
March 2024 |
May 2024 |
July 2024 |
Expiration Date:
December 7, 2023
Modified to Read (changes shown in bold italics):
Part 1. Overview Information
Key Dates
Open Date (Earliest Submission Date):
July 4, 2021
Letter of Intent Due Date(s):
30 days prior to application due date
|
Application Due Dates |
Review and Award Cycles |
||||
|
New |
Renewal / Resubmission / Revision (as allowed) |
AIDS |
Scientific Merit Review |
Advisory Council Review |
Earliest Start Date |
|
August 4, 2021 |
August 4, 2021 |
August 4, 2021 |
November 2021 |
January 2022 |
April 2022 |
|
December 6, 2021 |
December 6, 2021 |
December 6, 2021 |
March 2022 |
May 2022 |
July 2022 |
|
April 6, 2022 |
April 6, 2022 |
April 6, 2022 |
July 2022 |
October 2022 |
December 2022 |
|
August 4, 2022 |
August 4, 2022 |
August 4, 2022 |
November 2022 |
January 2023 |
April 2023 |
|
December 6, 2022 |
December 6, 2022 |
December 6, 2022 |
March 2023 |
May 2023 |
July 2023 |
|
April 6, 2023 |
April 6, 2023 |
April 6, 2023 |
July 2023 |
October 2023 |
December 2023 |
|
August 4, 2023 |
August 4, 2023 |
August 4, 2023 |
November 2023 |
January 2024 |
April 2024 |
|
December 6, 2023 |
December 6, 2023 |
December 6, 2023 |
March 2024 |
May 2024 |
July 2024 |
Expiration Date:
December 7, 2023
All other aspects of this FOA remain the same.
Will M. Aklin, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-5909
Email: aklinwm@nida.nih.gov
Kevin Walton, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-5980
Email: kevin.walton@nih.go